Intravenous belimumab plus SOC vs placebo plus SOC was not linked to an increased risk for infection among patients with SLE.

Cullinan's innovative approach and Zipalertinib's potential approval in 2026 position it as a promising biotech investment.

Last week Tuesday, PureTech had announced that Raju Kucherlapati stepped down immediately as chair and was replaced by Sharon Barber-Lui, who will be interim chair and also lead the process for ...